(Q34172595)

31 July 2017

1 reference

title

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more (English)

1 reference

31 July 2017

0 references

1 reference

0 references

1 reference

1 reference

1 reference

Brian L Pearlman

1

1 reference

31 July 2017

Nomi Traub

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

Clinical Infectious Diseases

31 July 2017

published in

1 reference

31 July 2017

volume

52

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

889-900

1 reference

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Occult hepatitis C virus infection: a new form of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Reversibility of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Reversal of hepatic fibrosis -- fact or fantasy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

A lymphotoxin-driven pathway to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Development of multicentric hepatocellular carcinoma after completion of interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Hepatitis C virus infection and incident type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

The natural history of hepatitis C with severe hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

The myth of occult hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR076

21 January 2018

Identifiers

DOI

10.1093/CID/CIR076

1 reference

31 July 2017

1 reference